Parulekar A A, Hakim Z S, Santani D D, Goyal R K
Department of Pharmacology, LM College of Pharmacy, Navrangpura, Ahmedabad, India.
Indian J Exp Biol. 1997 Nov;35(11):1182-6.
Present investigation was undertaken to study the effects of 6 week treatment with spirapril (2 mg/kg po) on insulin sensitivity, and serum lipid levels in streptozotocin (STZ)-diabetic and spontaneously hypertensive (SH) rats. Treatment of rats with spirapril in diabetic and diabetic with hypertensive animals significantly prevented STZ-induced loss of body weight, hypertension, and bradycardia. It also partially but significantly prevented STZ-induced hyperglycaemia in both diabetic Wistar and SH animals. Insulin level was not altered by spirapril treatment. There was significant reduction in cholesterol levels in the diabetic rats. In conclusion, the present investigation presents a number of beneficial effects of spirapril treatment in diabetic and/or hypertensive rats. Spirapril may be considered as one of the drugs of choice in treatment of hypertension when associated with diabetes
本研究旨在探讨用螺普利(2毫克/千克,口服)治疗6周对链脲佐菌素(STZ)诱导的糖尿病大鼠和自发性高血压(SH)大鼠胰岛素敏感性及血脂水平的影响。在糖尿病大鼠以及糖尿病合并高血压大鼠中,用螺普利治疗可显著预防STZ诱导的体重减轻、高血压和心动过缓。它还部分但显著地预防了STZ在糖尿病Wistar大鼠和SH大鼠中诱导的高血糖症。螺普利治疗未改变胰岛素水平。糖尿病大鼠的胆固醇水平显著降低。总之,本研究表明螺普利治疗对糖尿病和/或高血压大鼠有许多有益作用。当高血压与糖尿病并存时,螺普利可被视为治疗高血压的首选药物之一。